ALSO NOTED: Novartis may hand out cancer drug in Thailand; Abilify gets new use against major depression;

> Novartis may give Thailand free cancer meds if the country lays off its fight to compel drug makers to license generic versions of patented remedies. Report

> Bristol-Myers Squibb's antipsychotic med Abilify got the FDA's nod as an add-on therapy for major depression in patients who don't respond fully to antidepressants alone. Report

> Datamonitor predicts that sales of the Bayer/Onyx drug Nexavar will be "substantially boosted" by its new U.S. approval for treatment of inoperable liver cancer. Report

> Canadian students are abusing prescription painkillers at an unprecedented rate, according to a new survey. Report

And Finally... Need more evidence that stress can be a killer? The stress hormone norepinephrine appear to stimulate tumor-cell growth. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.